Los Angeles, October 13 /PRNewswire/ -- Clinical-stage medical technology company Sensydia today announced the initial closing of its latest financing round, which was oversubscribed and raised over $6 million, led by Colle Capital Partners and supported significantly by Orlando Health Ventures. The proceeds will be used to advance Sensydia’s Cardiac Performance System (CPS™) through the ACOUSTIC-1 study, facilitate FDA authorization, and support preparations for commercial launch.
CPS evaluates cardiac function by acquiring acoustic and electrical signals and analyzing them using artificial intelligence (AI) algorithms. The system is designed to enable clinicians to obtain pulmonary artery pressure assessments in nearly any clinical setting without invasive catheterization, helping to identify congestion and guide the diagnosis and treatment of heart failure and pulmonary hypertension.
In July 2026, a new Category III CPT® code, 1036T, became effective for non-invasive hemodynamic assessment based on three key elements: passive acquisition of acoustic and electrical signals; enhanced algorithmic analysis; and physician review, interpretation, and integration into clinical care—consistent with the approach adopted by CPS.
“The most important medical technology companies create categories, rather than compete within them,” said Bill Hawkins, retired Chairman and CEO of Medtronic and advisor to Sensydia. “Sensydia has the potential to bring pressure information to the point of care in a new way, with a foundation for scale.”
“Cardiologists treating heart failure need the right metrics at the right time and place. We built CPS to provide clinicians with objective pressure data right in the room where treatment decisions are made,” said Anthony Arnold, CEO of Sensydia. “With support from Colle Capital and Orlando Health Ventures, we are focused on rapidly bringing CPS to market to help patients with heart failure.”
“Sensydia built its CPS on catheter-based data—the clinical gold standard—and on a scale that few companies would attempt,” said Victoria Grace, Founding Partner at Colle Capital Partners. “This rigor, combined with the CPT codes already in place, gives us great confidence in this team. We’re proud to lead this funding round and support Sensydia.”
About Colle Capital Partners
Colle Capital Partners is a global, opportunity-driven early-stage technology venture capital fund. The firm invests at inception in AI-native businesses, deep tech, and infrastructure, supporting companies whose data creates proprietary moats. Learn more at colle.vc.
About Orlando Health Ventures
Orlando Health Ventures drives medical innovation through strategic investments in companies and technologies that are transforming and disrupting the healthcare industry. By collaborating with clinicians, team members, and leadership, Orlando Health Ventures identifies, evaluates, and invests in innovative companies with high growth potential that align with Orlando Health’s mission to deliver high-quality care. The venture arm invests in healthcare technology, biotechnology, and service companies poised to improve patient outcomes and/or enhance workflows across the healthcare system. Learn more at orlandohealth.com/ventures.
About Sensydia
Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform designed to provide clinicians in office or outpatient settings with rapid, safe, and accurate hemodynamic function assessments to enhance the diagnosis and management of heart failure and pulmonary hypertension, ultimately improving patient outcomes. CPS has received FDA Breakthrough Device designation. The company’s regulatory history also includes FDA 510(k) clearance in 2018 for its algorithm used in non-invasive measurement of ejection fraction.
This press release contains forward-looking statements regarding Sensydia’s clinical, regulatory, and commercial plans. Actual results may differ materially from these statements, and Sensydia undertakes no obligation to update them.
For research purposes only. CPS has not been authorized by the FDA.
CPT® is a registered trademark of the American Medical Association.